ArticleInternational urology and nephrology2025
The impact of end-stage kidney disease on hospitalization outcomes in patients with complete heart block: insights from united states population data.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with end stage kidney disease (ESKD) suffer higher rates of mortality, partly because of cardiac conduction abnormalities. Despite this, data on complete heart block (CHB) cases in patients with ESKD remain limited.
methodsAdmissions for CHB were identified in the 2016-2019 National Inpatient Sample. In-hospital outcomes were compared between patients with and without ESKD. The primary outcome was mortality. Secondary outcomes included, Permanent Pacemaker (PPM) and Temporary Pacemaker (TPM) use, palliative care, vasopressor use, mechanical ventilation use, length of stay (LOS), and total charges. Multivariable regression models were used to adjust for confounders.
resultsAmong 150,265 hospitalizations with a primary diagnosis of CHB, 5,109 (3.4%) had a diagnosis of ESKD. ESKD was associated with higher odds of mortality (adjusted Odds Ration [aOR] 1.54, 95% CI 1.15-2.07), vasopressors use (aOR 1.9, 95% CI 1.25-2.88), mechanical ventilation (aOR 1.26, 95% CI 1.03-1.56), palliative care (aOR 1.41, 95% CI 1.03-1.94), TPM use (aOR 1.26, 95% CI 1.09-1.47), lower odds of PPM use (aOR 0.54, 95% CI 0.47-0.62), longer LOS (+ 1.29 days, p < 0.001) and higher charges ($123,110 vs. $87,235, p < 0.001).
conclusionPatients with ESKD admitted for CHB had higher fatal and non-fatal adverse outcomes compared to patients without ESKD.
Indexed as
Identifiers
40186731What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.